About us

Immunovia AB was founded in 2007 by researchers from the Department of Immunotechnology at Lund University and CREATE Health (the Center for Translational Cancer Research) in Lund, Sweden.

Our strategy is to decipher the wealth of information available in blood – and translate it into clinically useful tools to diagnose complex diseases such as cancer and autoimmune disorders, earlier and more accurately than previously possible.

Immunovia’s unique technology platform – IMMray™ – is an antibody-based multiplex test that is designed to provide a snapshot of the immune system response – based on the information available in a single drop of blood.

But IMMray™ is more than a technology, it is a systematic approach, based on cutting-edge bioinformatics, to finding the most clinically relevant changes that appear in the blood, and combining this knowledge into a “disease fingerprint” – also called a biomarker signature – that is highly specific to the particular disease.

In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts. The IMMray™ PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancer, will be offered as laboratory developed test (LDT) exclusively through Immunovia, Inc in the second quarter of 2021. Link to blinded validation study poster USA

Immunovia has also developed a pipeline of projects that are in the discovery phase. These early projects target the development of biomarker signatures for other cancers such as lung cancer as well as autoimmune diseases. An autoimmune development program has been initiated at Immunovia based on very good results from a differential diagnosis study of SLE versus RA, Sjögrens syndrome and Vasculitis.

Immunovia has been a listed company since 2015, with shares traded (as IMMNOV) on Nasdaq First North in Stockholm and since 3 April 2018 traded on Nasdaq Stockholm. The company is headquartered in Lund, Sweden. In the same location, Immunovia Dx Laboratory will comply with the rules and regulations set for testing services in the European markets. .

For more information, please visit



  1. Ingvarsson J et al.Proteomics 2008 8(11):2211-9.
  2. Wingren et al. Cancer Res. 2012 15;72(10):2481-90.
  3. Gerdtsson et al. Int Journal of Proteomics 2015;2015:587250.
  4. Gerdtsson et al. J Mol Oncol, 2016. 10, 1305-1316.
  5. Mellby et al. Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer. J Clin Oncol. 2018 Aug 14. doi: 10.1200/JCO.2017.77.6658. 

Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form. Please check the junk mail if you cannot find the message.

Press releases
Financial reports